- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02572388
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. The vaccine R21 will either be administered alone or in combination with the adjuvant vaccine Matrix-M1.
All vaccinations will be administered intramuscularly. Each volunteer will receive three vaccinations in total.
There are three different vaccine schedules:
Group 1 will receive 10µg of R21 mixed with 50µg of Matrix-M1 on days 0, 28, and 56.
Group 2 will receive 50µg of R21 on days 0, 28, and 56. .
Group 3 will receive 50µg of R21 mixed with 50µg of Matrix-M1 on days 0, 28, and 56.
The study will assess the safety of the vaccines, and the immune responses to the vaccinations. Immune responses are measured by tests on blood samples.
Healthy adult volunteers will be recruited in Oxford and London, England.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
London, Reino Unido, W12 0HS
- NIHR Wellcome Trust Clinical Research Facility, Hammersmith Hospital
-
-
Oxfordshire
-
Oxford, Oxfordshire, Reino Unido, OX3 7LE
- Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The volunteer must satisfy all the following criteria to be eligible for the study:
- Healthy adults aged 18 to 50 years
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
- For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination
- Agreement to refrain from blood donation during the course of the study
- Provide written informed consent
Exclusion Criteria:
The volunteer may not enter the study if any of the following apply:
- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
- Any history of anaphylaxis in relation to vaccination
- Pregnancy, lactation or willingness/intention to become pregnant during the study
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- History of serious psychiatric condition likely to affect participation in the study
- Any other serious chronic illness requiring hospital specialist supervision
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
- Suspected or known injecting drug abuse in the 5 years preceding enrolment
- Seropositive for hepatitis B surface antigen (HBsAg)
- Seropositive for hepatitis C virus (antibodies to HCV)
- History of clinical malaria (any species)
- Travel to a malaria endemic region during the study period or within the previous six months
- Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
- Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Group 1
10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
|
|
Comparador activo: Group 2
50µg of R21 on days 0, 28, and 56.
|
|
Comparador activo: Group 3
50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
|
|
Comparador activo: Group 4
2µg of R21 mixed with 50µg of Matrix-M
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Safety and Tolerability of Administration of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events.
Periodo de tiempo: Assessment of solicited AEs in the first 7 days post vaccination.
|
Occurrence of solicited local and systemic adverse events (i.e: pain, redness, swelling and pruritus at injection site and temperature, feverishness, myalgia, arthralgia, malaise, headache and nausea).
|
Assessment of solicited AEs in the first 7 days post vaccination.
|
Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Unsolicited Adverse Events.
Periodo de tiempo: Unsolicited AEs to be assessed up to 28 days post vaccination.
|
Occurrence of unsolicited local and systemic adverse events.
|
Unsolicited AEs to be assessed up to 28 days post vaccination.
|
Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Serious Adverse Events.
Periodo de tiempo: 6 months
|
Occurrence of serious adverse events collected from enrolment until the end of the follow-up period.
|
6 months
|
Safety and Tolerability of R21 With and Without the Adjuvant Matrix-M1 Assessed by the Occurrence of Laboratory Adverse Events.
Periodo de tiempo: At Day 0 (baseline), day 7 and day 28 post vaccination
|
Occurrence of laboratory adverse events defined as clinically significant changes from baseline.
Haematology (Full Blood Count) and Biochemistry (Kidney and Liver Function Tests) will be assessed.
|
At Day 0 (baseline), day 7 and day 28 post vaccination
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- VAC053
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre R21
-
University of OxfordTerminado
-
University of OxfordBill and Melinda Gates Foundation; University Hospitals Bristol and Weston NHS...ReclutamientoPaludismo, FalciparumReino Unido
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...ReclutamientoPaludismo, Plasmodium falciparumGambia
-
European Vaccine InitiativeUniversity of Oxford; Malaria Research and Training Center, Bamako, MaliAún no reclutando
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Institut...TerminadoPaludismo, FalciparumBurkina Faso
-
University of OxfordTerminado
-
University of OxfordTerminado
-
University of OxfordMRC/UVRI and LSHTM Uganda Research UnitActivo, no reclutando
-
Rio de Janeiro State UniversityUniversidade Federal Fluminense; Rio de Janeiro State Research Supporting Foundation...ReclutamientoDepresión | Calidad de vida | Obesidad | Desórdenes de ansiedad | Variabilidad del ritmo cardíacoBrasil
-
University of OxfordTerminadoPaludismo, FalciparumTailandia